BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO - US0905722072 - Common Stock
323.82 USD
+4.74 (+1.49%)
323.82 USD
0 (0%)
BIO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. While BIO has a great health rating, its profitability is only average at the moment. BIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year BIO was profitable.
In the past year BIO had a positive cash flow from operations.
In multiple years BIO reported negative net income over the last 5 years.
Each year in the past 5 years BIO had a positive operating cash flow.
1.2 Ratios
BIO has a Return On Assets of -6.97%. This is comparable to the rest of the industry: BIO outperforms 52.63% of its industry peers.
BIO has a Return On Equity (-10.03%) which is in line with its industry peers.
With a decent Return On Invested Capital value of 2.26%, BIO is doing good in the industry, outperforming 61.40% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BIO is significantly below the industry average of 13.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
BIO has a Operating Margin of 10.27%. This is in the better half of the industry: BIO outperforms 70.18% of its industry peers.
BIO's Operating Margin has been stable in the last couple of years.
With a decent Gross Margin value of 52.42%, BIO is doing good in the industry, outperforming 63.16% of the companies in the same industry.
BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
BIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
BIO has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BIO has been reduced compared to 5 years ago.
The debt/assets ratio for BIO is higher compared to a year ago.
2.2 Solvency
BIO has an Altman-Z score of 3.49. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
BIO has a better Altman-Z score (3.49) than 66.67% of its industry peers.
BIO has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO would need 3.57 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.57, BIO is in the better half of the industry, outperforming 77.19% of the companies in the same industry.
BIO has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
BIO's Debt to Equity ratio of 0.18 is in line compared to the rest of the industry. BIO outperforms 57.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.49 |
ROIC/WACC0.21
WACC10.62%
2.3 Liquidity
A Current Ratio of 5.44 indicates that BIO has no problem at all paying its short term obligations.
BIO has a Current ratio of 5.44. This is amongst the best in the industry. BIO outperforms 85.96% of its industry peers.
BIO has a Quick Ratio of 3.94. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.94, BIO is in the better half of the industry, outperforming 68.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
The earnings per share for BIO have decreased by -1.90% in the last year.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
The Revenue has decreased by -0.88% in the past year.
Measured over the past years, BIO shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
BIO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.66% yearly.
The Revenue is expected to grow by 1.26% on average over the next years.
EPS Next Y-2.19%
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
EPS Next 5Y-2.66%
Revenue Next Year0.15%
Revenue Next 2Y1.2%
Revenue Next 3Y2.07%
Revenue Next 5Y1.26%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 31.41, the valuation of BIO can be described as expensive.
Based on the Price/Earnings ratio, BIO is valued a bit cheaper than 71.93% of the companies in the same industry.
BIO is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 31.44 indicates a quite expensive valuation of BIO.
BIO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 68.42% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.92, BIO is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.41 | ||
| Fwd PE | 31.44 |
4.2 Price Multiples
78.95% of the companies in the same industry are more expensive than BIO, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.94 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)4.01
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
5. Dividend
5.1 Amount
No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
323.82
+4.74 (+1.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.92%
Inst Owner Change0.07%
Ins Owners8.18%
Ins Owner Change0%
Market Cap8.73B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (11.82%)
Short Float %4.91%
Short Ratio4.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)14.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.58%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)3.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.14%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)-0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.41 | ||
| Fwd PE | 31.44 | ||
| P/S | 3.41 | ||
| P/FCF | 25.94 | ||
| P/OCF | 17.77 | ||
| P/B | 1.3 | ||
| P/tB | 1.51 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.18%
EPS(NY)10.3
Fwd EY3.18%
FCF(TTM)12.48
FCFY3.86%
OCF(TTM)18.22
OCFY5.63%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)4.01
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.49 |
F-Score5
WACC10.62%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-2.19%
EPS Next 2Y-0.04%
EPS Next 3Y3.67%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.15%
Revenue Next 2Y1.2%
Revenue Next 3Y2.07%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.67%
EBIT Next 3Y14.51%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
Can you provide the valuation status for BIO-RAD LABORATORIES-A?
ChartMill assigns a valuation rating of 2 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for BIO stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to decline by -2.19% in the next year.